Minimal residual disease (MRD) has become a major tool in the monitoring of hematological malignancies; however, its utility can be…
Browsing: Acute Lymphoblastic Leukemia
Minimal residual disease (MRD) is a hot topic in the world of oncology and many talks on the topic were…
Could the progression of smoldering multiple myeloma (SMM) be better predicted? In this interview, Irene Ghobrial, MD, from the Dana-Farber…
The primary focus is often on treatment within the United States or Europe, but what about treatment on a global…
As high-risk patients with multiple myeloma (MM) continue to die from the disease, novel treatments are needed. In this interview,…
Although genetics and epigenetics serve an important role in the efficacy of novel agents such as ibrutinib, other factors must…
With new developments in the treatment of patients with chronic lymphocytic leukemia (CLL), is there a possibility of eradicating the…
As lung cancer screening is a relatively new area, particularly to non-healthcare professionals, understanding of the procedure and risks involved…
Tian Zhang, MD Duke University Medical Center, VEGF is Immunomodulatory & Decreases Regulatory T-Cell Responses Significant progress in the field…
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real…
André P Fay, MD Hospital Mãe De Deus Cancer Institute, discusses Impact of Geographic Region in Clinical Outcome of Metastatic…
Tian Zhang, MD Duke University Medical Center, discusses Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov…
Robert Uzzo, MD Fox Chase Cancer Center, discusses Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive…
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Canada Negotiates Drug Prices w Pan-Canadian Consortium Sunitinib & Pazopanib are most…
Tian Zhang, MD Duke University Medical Center, discusses Early Phase VEGF Trials Enhance Responses in the 1st Line Could lead…
Robert Uzzo, MD Fox Chase Cancer Center, discusses Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery…
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had…
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still…
Following cancer treatment, it is important to support and enable an increasing number of cancer survivors to live as healthy…
Following the promising results of initial investigations into the use of an electronic healthcare assessment tool in the delivery of…
Integrating technology into healthcare service delivery can improve patient experience whilst improving efficiency. In this interview, Pamela Rose, Macmillan Lung…
Disease monitoring is important to determine what is happening with patients outside of the clinical setting. Speaking from the American…
Exciting advancements in acute myeloid leukemia (AML) research were discussed during the American Society of Hematology (ASH) 2017 Annual Meeting…
Despite the remarkable progress being made in the treatment of patients with acute promyelocytic leukemia (APL), a high rate of…
CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual…
Over the past year, several exciting new agents for the treatment of acute lymphoblastic leukemia (ALL) have been approved. In…
There have recently been a number of major drug approvals for the treatment of acute lymphoblastic leukemia (ALL). One such…
We need to understand the mechanisms of drug resistance in order to prevent it, in addition to informing subsequent treatment…
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage…
The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid…
The majority of patients with advanced systemic mastocytosis (AdvSM) exhibit D816V mutations of the KIT gene, which presents a promising…
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin was approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), the most…
Next-generation antibody-drug conjugates (ADCs) are demonstrating improved safety and tolerability compared with their predecessors. Speaking from the American Society of…
With the increasing complexity of clinical trials, the role of the Clinical Research Nurse (CRN) and the Clinical Nurse Specialist…
Staff within the NHS are very busy and work pressures can result in less time for communication between nurses. In…
What can be done to improve the experience of clinical trials for patients who participate? In this interview, recorded at…
Different NHS trusts work in different ways; what could be considered the best practice in one trust may not be…
The identification of novel therapeutic targets is essential for the improved treatment of hematological cancer, particularly due to the development…
We know that CAR T-cell therapy is effective in the treatment of chronic lymphocytic leukemia (CLL); however, a current limitation…
There is not a large amount of data available to allow clinicians to determine whether patients should remain on or…
Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial…
The current standard of care for frontline kidney cancer is tyrosine kinase inhibitor (TKI) treatment. Now there are a host…
The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert…
Long-term follow-up data is the real determinant of the efficacy of novel therapies. Here, Robert Jones, PhD, of the University…
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the…
The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy…
Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease…
There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that…
This interview provides an exciting insight into the Translational Research Training in Hematology (TRTH) and the Clinical Research Training in…
It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with…